Health Care · Pharmaceutical Preparations

KRRO Korro Bio, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1703647116 filings
Russell 2000

KRRO at a glance

Korro Bio, Inc. (KRRO, SEC CIK 1703647) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Korro Bio, Inc. (KRRO) reported revenue of $6.4 million (up 181.5% from FY2024) and a net loss of $117.3 million. Diluted EPS was -$12.48.
  • As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Korro Bio, Inc. (KRRO) shares worth $29.5 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by FORMELA JEAN FRANCOIS on November 12, 2026 of 33,175 shares at $14.30 per share.
  • In the last 90 days, KRRO insiders reported 4 open-market purchases ($885K) and 15 open-market sales ($1.8M) on Form 4, a net sale of $879K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$6.4M
+181.5% vs prior year
Insiders · 90 days
4 buys · 15 sells
Net −$879K
13F holders
21 funds
$29.5M · −2 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02 · Item 1.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly collaboration revenue $0.0M, down $1.1M YoY
  • Net loss $17.5M vs $18.1M YoY, operating loss $18.5M vs $19.2M
  • KRRO-121 R&D $2.2M, up $1.9M YoY, strongest disclosed program growth
  • KRRO-110 R&D down $3.6M following REWRITE trial termination, weakest disclosed program
  • Cash $124.8M, operating cash outflow $46.0M, $85.3M financing inflow, runway into second half of 2028

Risk Factors

  • Newly intensified healthcare regulation: CMS finalized GLOBE in September 2026, with Medicare Part B implementation scheduled for January 1, 2027
  • Most material clinical risk: KRRO-121 remains tested only in limited healthy volunteers, with no UCD or HE patient data
  • Regulatory risk: FDA has not reviewed ANCHOR under an IND, and Part 2 requires regulatory approval
  • Operational risk: UCD rarity and specialized metabolic centers could delay ANCHOR Part 2 enrollment and the second-half 2027 interim readout
  • Financial risk: $124.8 million in cash, equivalents and marketable securities funds operations only into the second half of 2028, without committed additional capital

AI summary of the KRRO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Korro Bio announced financial results for the quarter ended September 30, 2026
  • Full quarterly results and management commentary appear in Exhibit 99.1, the accompanying press release

Item 1.02: Termination of a Material Definitive Agreement

  • Novo Nordisk termination effective February 1, 2027, ending the collaboration after its 12-month hold period
  • Korro retains the $10.0 million upfront payment and faces no early termination penalties

Item EX-99.1: Item EX-99.1

  • Q3 2026 clinical execution: KRRO-121 dosing began in healthy volunteers, with UCD patient dosing targeted for first half 2027
  • KRRO-121 interim ANCHOR data targeted for second half 2027, creating the next major clinical catalyst
Filed Oct 22, 2026Full analysis →

Item 8.01: Other Events

  • KRRO announced preclinical results for KRRO-111, its candidate for Alpha-1 Antitrypsin Deficiency
  • Results represent an early development milestone, with clinical efficacy and safety still unestablished

Item EX-99.1: Item EX-99.1

  • KRRO-111 achieved 96% SERPINA1 mRNA editing in repeat-dose mice, with M-AAT comprising 93% of circulating AAT
  • Total AAT reached 172 μM, approximately 6-fold versus vehicle, at Day 57
Filed Oct 5, 2026Full analysis →

Item 8.01: Other Events

  • First ANCHOR cohort dosed, advancing KRRO-121 into Phase 1/2 clinical testing
  • KRRO-121 targets hyperammonemia in urea cycle disorders and hepatic encephalopathy

Item EX-99.1: Item EX-99.1

  • First cohort dosed in Phase 1/2 ANCHOR trial, advancing KRRO-121 from preclinical testing into human safety evaluation
  • Single 2mg/kg dose administered to healthy volunteers, with placebo-controlled SAD and MAD studies planned for up to 50 participants

AI summaries of KRRO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for KRRO

Don't miss the next KRRO filing

  • Alerts as it files. A push when KRRO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut KRRO, by share count.
  • Ask anything. An AI agent that reads every KRRO filing and answers with sources.

KRRO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
FORMELA JEAN FRANCOISSellNov 12, 2026$14.30
FORMELA JEAN FRANCOISSellNov 12, 2026$14.30
FORMELA JEAN FRANCOISSellNov 11, 2026$15.00
FORMELA JEAN FRANCOISSellNov 11, 2026$15.60
FORMELA JEAN FRANCOISSellNov 11, 2026$15.60
FORMELA JEAN FRANCOISSellNov 11, 2026$15.00
Lynx1 Capital Management LPBuyOct 26, 2026$11.75
Lynx1 Capital Management LPBuyOct 23, 2026$12.11

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.3M$6.4M
Operating Income--$91.9M-$121.9M
Net Income-$81.2M-$83.6M-$117.3M
Op. Margin--4047.1%-1906.4%
Net Margin--3680.4%-1834.5%
Balance Sheet
Total Assets-$226.2M$113.5M
Equity$169.9M$160.4M$51.4M
ROE-47.8%-52.1%-228.0%
Per Share
EPS-$-9.37$-12.48
Cash Flow
Operating CF-$67.3M-$60.1M-$78.6M
CapEx$7.8M$17.9M$518K

Source: XBRL data in Korro Bio, Inc. (KRRO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate KRRO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
KRRO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202621$29.5M
Q2 202623$40.6M
Q1 202620$23.1M
Q4 202519$16.6M
Q3 202519$139.8M
Q2 202517$32.5M
Q1 202515$30.9M
Q4 202412$68.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 146 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

KRRO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Oct 26, 2026--
8-KOct 22, 2026Analysis-
8-KOct 5, 2026Analysis-
4Sep 15, 2026--
4Sep 14, 2026--
4Sep 10, 2026--
4Aug 28, 2026--
4Aug 21, 2026--
8-KAug 19, 2026Analysis-
4Aug 13, 2026--
4Aug 13, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Aug 5, 2026--
SC 13GJul 29, 2026-
4Jul 17, 2026--
4Jul 17, 2026--
4Jul 17, 2026--
4Jul 17, 2026--
4Jul 7, 2026--
4Jun 24, 2026--
4Jun 17, 2026--

Related Health Care companies

All Health Care →

KRRO SEC filings: frequently asked questions

Are KRRO insiders buying or selling?

In the last 90 days, Korro Bio, Inc. (KRRO) officers, directors and 10% owners reported 4 open-market purchases worth $884,752 by 1 insider and 15 open-market sales worth $1.8 million by 2 insiders on Form 4, a net sale of $878,658. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold KRRO stock?

As of September 30, 2026, the largest Korro Bio, Inc. (KRRO) holders among the 13F filers tracked by SignalX were BlackRock ($8.4 million), Vanguard Capital Management LLC ($4.7 million), JPMorgan Chase & Co ($2.9 million), State Street Corp ($2.4 million), Vanguard Portfolio Management LLC ($2.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was KRRO's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Korro Bio, Inc. (KRRO) reported revenue of $6.4 million (up 181.5% from FY2024) and a net loss of $117.3 million. Diluted EPS was -$12.48. The figures come from the XBRL data in the 10-K.

What did KRRO report in its latest 8-K?

Korro Bio, Inc. (KRRO) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 1.02 (Termination of a Material Definitive Agreement). Korro Bio announced financial results for the quarter ended September 30, 2026.

What are the latest KRRO SEC filings?

Korro Bio, Inc. (KRRO) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.

What is KRRO's SEC CIK number?

Korro Bio, Inc. (KRRO)'s SEC Central Index Key (CIK) is 1703647. EDGAR lists every KRRO filing under that number.

Ask anything about KRRO

The research agent reads KRRO's filings, financials, insider trades and 13F holders, then answers with sources.